Unibest
← Back to patent-cliff list

Lenumlostat hydrochloride

Tier C — Watch / trade

Lenumlostat hydrochloride

Pharmakea Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type

Targets:LOXL2

Indications (approved):Myelofibrosis, Essential thrombocythaemia, Polycythaemia vera

Regional status

US
Phase II
2019-07-24
EU
Phase II
2021-06-09
China
-
Japan
-

Synthetic routes & intermediates1 routes

Originator routes × 1Optimised (non-patent) × 0Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 1Steps 7 · Total yield 89 mg
PAT-1251-0011196155-38-0PAT-1251-00219438-10-9PAT-1251-0032007887-91-2PAT-1251-0042007887-92-3PAT-1251-0052007887-93-4PAT-1251-0062007887-67-2PAT-1251-0072006333-41-9PAT-1251-0082099683-12-0PAT-1251-0092098884-52-5API · Lenumlostat hydrochloride
CodeCAS No.Intermediate
PAT-1251-0011196155-38-02-chloro-6-(trifluoromethyl)isonicotinonitrile
PAT-1251-00219438-10-9methyl 3-hydroxybenzoate
PAT-1251-0032007887-91-2methyl 3-((4-cyano-6-(trifluoromethyl)pyridin-2-yl)oxy)benzoate
PAT-1251-0042007887-92-3methyl 3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzoate
PAT-1251-0052007887-93-4methyl 3-((4-(((tert-butoxycarbonyl)amino)methyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzoate
PAT-1251-0062007887-67-23-((4-(((tert-butoxycarbonyl)amino)methyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzoic acid
PAT-1251-0072006333-41-9(3S,4S)-4-fluoropyrrolidin-3-ol hydrochloride
PAT-1251-0082099683-12-0tert-butyl ((2-(3-(3-fluoro-4-hydroxypyrrolidine-1-carbonyl)phenoxy)-6-(trifluoromethyl)pyridin-4-yl)methyl)carbamate
PAT-1251-0092098884-52-5(3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)((3R,4R)-3-fluoro-4-hydroxypyrrolidin-1-yl)methanone

Frequently asked questions

What are the approved indications of Lenumlostat hydrochloride?

Approved indications include: Myelofibrosis, Essential thrombocythaemia, Polycythaemia vera.

When does the Lenumlostat hydrochloride patent expire?

No public expiry year is available for Lenumlostat hydrochloride yet; this page updates once verified.

How many synthesis routes are recorded for Lenumlostat hydrochloride?

1 synthesis routes are recorded; the shortest is 7 steps with 89 mg total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Lenumlostat hydrochloride intermediates?

All intermediates in Lenumlostat hydrochloride routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.

How do I get a quote for Lenumlostat hydrochloride intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-10-07